MSU
JSPRW icon

Mizuho Securities USA’s Japer Therapeutics Warrants JSPRW Stock Holding History

Mizuho Securities USA’s Portfolio JSPRW Stock Details JSPRW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-16,558
Closed -$11K – 141
2020
Q1 		$11K Buy
+16,558
New +$13K ﹤0.01% 113

Other funds holding JSPRW

OCAM
Owl Creek Asset Management New York $1.38B AUM 59.67% 1-Year Est. Return
SRCM
Sage Rock Capital Management New York $22.3M AUM 4.09% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
TCM
Tenor Capital Management New York $6.49B AUM 3.01% 1-Year Est. Return
PMAM
Picton Mahoney Asset Management Toronto, Ontario, Canada $13.5B AUM 50.48% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
MS
Maven Securities St Helier, Jersey $5.2B AUM 44.01% 1-Year Est. Return
LIM
Longfellow Investment Management Boston, Massachusetts $480M AUM 8% 1-Year Est. Return

Mizuho Securities USA's JSPRW Position: Q2 2020 in Review

Mizuho Securities USA sold out of Japer Therapeutics Warrants (JSPRW) in Q2 2020, closing a stake of 16,558 shares — an estimated $11K sold.

Mizuho Securities USA first reported a position in JSPRW in Q1 2020 and held it in 1 quarter. The position peaked at $11K in Q1 2020. 25 funds tracked by Wall St. Rank hold JSPRW as of Q2 2020.

  • Mizuho Securities USA reported no remaining Japer Therapeutics Warrants position as of Q2 2020 after selling out during the quarter.
  • Mizuho Securities USA sold 16,558 Japer Therapeutics Warrants shares in Q2 2020, an estimated $11K.
  • Mizuho Securities USA first reported a position in Japer Therapeutics Warrants in Q1 2020 and held it in 1 quarter.
  • Mizuho Securities USA's Japer Therapeutics Warrants position peaked at $11K in Q1 2020.
  • 25 funds tracked by Wall St. Rank held Japer Therapeutics Warrants as of Q2 2020.

Based on Mizuho Securities USA's 13F filing for Q2 2020, filed 27 Jul 2020.